Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib
about
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaMultiple myeloma in the marrow: pathogenesis and treatments.Arterial stiffness in hematologic malignancies.Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
P2860
Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Overview and management of car ...... with single-agent carfilzomib
@ast
Overview and management of car ...... with single-agent carfilzomib
@en
Overview and management of car ...... with single-agent carfilzomib
@nl
type
label
Overview and management of car ...... with single-agent carfilzomib
@ast
Overview and management of car ...... with single-agent carfilzomib
@en
Overview and management of car ...... with single-agent carfilzomib
@nl
prefLabel
Overview and management of car ...... with single-agent carfilzomib
@ast
Overview and management of car ...... with single-agent carfilzomib
@en
Overview and management of car ...... with single-agent carfilzomib
@nl
P1433
P1476
Overview and management of car ...... with single-agent carfilzomib
@en
P2093
Michael Wang
P407
P478
27 Suppl 3
P577
2013-12-01T00:00:00Z